Eliot Godofsky

1.7k total citations
27 papers, 1.2k citations indexed

About

Eliot Godofsky is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Eliot Godofsky has authored 27 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hepatology, 14 papers in Epidemiology and 8 papers in Infectious Diseases. Recurrent topics in Eliot Godofsky's work include Hepatitis C virus research (16 papers), Hepatitis B Virus Studies (9 papers) and HIV/AIDS drug development and treatment (7 papers). Eliot Godofsky is often cited by papers focused on Hepatitis C virus research (16 papers), Hepatitis B Virus Studies (9 papers) and HIV/AIDS drug development and treatment (7 papers). Eliot Godofsky collaborates with scholars based in United States, United Kingdom and Spain. Eliot Godofsky's co-authors include Edwin DeJesus, Jeffrey M. Jacobson, Daniel R. Kuritzkes, Eric Lawitz, Nezam H. Afdhal, Ira M. Jacobson, Jeffrey A. Larson, Stanley T. Lewis, Steven P. Weinheimer and M. Rodríguez‐Torres and has published in prestigious journals such as Hepatology, The American Journal of Medicine and The Journal of Infectious Diseases.

In The Last Decade

Eliot Godofsky

27 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eliot Godofsky United States	19	765	762	508	283	121	27	1.2k
Mary‐Anne Trabaud France	21	860 1.1×	975 1.3×	480 0.9×	355 1.3×	188 1.6×	55	1.6k
Barbara McGovern United States	5	831 1.1×	1.0k 1.3×	385 0.8×	186 0.7×	273 2.3×	7	1.4k
Hacène Khiri France	22	958 1.3×	738 1.0×	333 0.7×	193 0.7×	42 0.3×	62	1.3k
Ann Wyseur Belgium	8	1.1k 1.5×	1.3k 1.7×	351 0.7×	196 0.7×	38 0.3×	10	1.5k
Giulia Morsica Italy	18	1.0k 1.3×	1.1k 1.4×	241 0.5×	86 0.3×	39 0.3×	73	1.3k
Motokazu Mukaide Japan	19	1.3k 1.7×	1.3k 1.7×	367 0.7×	81 0.3×	52 0.4×	45	1.7k
Rosemary Ffrench Australia	20	748 1.0×	687 0.9×	198 0.4×	300 1.1×	488 4.0×	43	1.5k
Harvey J. Alter United States	6	1.7k 2.2×	1.9k 2.5×	329 0.6×	138 0.5×	181 1.5×	7	2.4k
Paul Neuwald United States	15	1.7k 2.2×	1.7k 2.3×	409 0.8×	309 1.1×	82 0.7×	20	2.3k
Françoise Stoll‐Keller France	19	581 0.8×	666 0.9×	99 0.2×	94 0.3×	151 1.2×	46	915

Countries citing papers authored by Eliot Godofsky

Since Specialization

Citations

This map shows the geographic impact of Eliot Godofsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eliot Godofsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eliot Godofsky more than expected).

Fields of papers citing papers by Eliot Godofsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eliot Godofsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eliot Godofsky. The network helps show where Eliot Godofsky may publish in the future.

Co-authorship network of co-authors of Eliot Godofsky

This figure shows the co-authorship network connecting the top 25 collaborators of Eliot Godofsky. A scholar is included among the top collaborators of Eliot Godofsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eliot Godofsky. Eliot Godofsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lawitz, Eric, Edwin DeJesus, Eric M. Yoshida, et al.. (2015). Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2). Hepatology. 64(2). 360–369. 142 indexed citations

Lawitz, Eric, E DeJesus, Eric M. Yoshida, et al.. (2015). LP04 : A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: Optimist-2. Journal of Hepatology. 62. S264–S265. 50 indexed citations

Lalezari, Jacob, Terry Box, William O’Riordan, et al.. (2013). Idx184 in Combination with Pegylated Interferon-α2A and Ribavirin for 2 Weeks in Treatment-Naive Patients with Chronic Hepatitis C. Antiviral Therapy. 18(6). 755–764. 9 indexed citations

Wedemeyer, Heiner, Donald M. Jensen, Eliot Godofsky, et al.. (2012). Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents. Hepatology. 56(6). 2398–2403. 27 indexed citations

Godofsky, Eliot. (2012). Why Should Infectious Disease Physicians Care for the Hepatitis C–Infected Patient?. Infectious Disease Clinics of North America. 26(4). 839–847. 1 indexed citations

Lawitz, Eric, Eliot Godofsky, Roman Rouzier, et al.. (2011). Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy. Antiviral Research. 89(3). 238–245. 58 indexed citations

Lalezari, Jacob, F. Poordad, P. Mehra, et al.. (2010). 2013 ANTIVIRAL ACTIVITY, PHARMACOKINETICS AND SAFETY OF IDX184 IN COMBINATION WITH PEGYLATED INTERFERON (PEGIFN) AND RIBAVIRIN (RBV) IN TREATMENT-NAIVE HCV GENOTYPE 1-INFECTED SUBJECTS. Journal of Hepatology. 52. S469–S469. 18 indexed citations

Poordad, F., E. Läwitz, M. Shiffman, et al.. (2009). 14 EFFICACY AND SAFETY OF WEIGHT-BASED REGIMENS OF TARIBAVIRIN OR RIBAVIRIN, GIVEN WITH PEGINTERFERON ALFA-2B, AT 12 WEEKS AFTER TREATMENT (SVR12) IN NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC-HEPATITIS C. Journal of Hepatology. 50. S8–S8. 2 indexed citations

Jacobson, Jeffrey M., Daniel R. Kuritzkes, Eliot Godofsky, et al.. (2008). Safety, Pharmacokinetics, and Antiretroviral Activity of Multiple Doses of Ibalizumab (formerly TNX-355), an Anti-CD4 Monoclonal Antibody, in Human Immunodeficiency Virus Type 1-Infected Adults. Antimicrobial Agents and Chemotherapy. 53(2). 450–457. 125 indexed citations

10.

Wright, David H., Eliot Godofsky, Sharon Walmsley, et al.. (2008). Efficacy and Safety of 48 Weeks of Enfuvirtide 180 mg Once-Daily Dosing Versus 90 mg Twice-Daily Dosing in HIV-Infected Patients. HIV Clinical Trials. 9(2). 73–82. 10 indexed citations

11.

Tebas, Pablo, Christopher Lucasti, Gary Richmond, et al.. (2008). Enfuvirtide Does Not Require Dose Adjustment in Patients With Chronic Kidney Failure. JAIDS Journal of Acquired Immune Deficiency Syndromes. 47(3). 342–345. 15 indexed citations

12.

Pockros, Paul J., David R. Nelson, Eliot Godofsky, et al.. (2008). R1626 plus peginterferon Alfa‐2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin†. Hepatology. 48(2). 385–397. 74 indexed citations

13.

Nelson, Daniel, Paul J. Pockros, Eliot Godofsky, et al.. (2008). 993 HIGH END-OF-TREATMENT RESPONSE (84%) AFTER 4 WEEKS OF R1626, PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN FOLLOWED BY A FURTHER 44 WEEKS OF PEGINTERFERON ALFA-2A AND RIBAVIRIN. Journal of Hepatology. 48. S371–S371. 23 indexed citations

14.

Dore, Gregory J., Francesca J. Torriani, M. Rodríguez‐Torres, et al.. (2007). Baseline factors prognostic of sustained virological response in patients with HIV–hepatitis C virus co-infection. AIDS. 21(12). 1555–1559. 23 indexed citations

15.

Jacobson, Ira M., Robert S. Brown, Bradley Freilich, et al.. (2007). Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients. Hepatology. 46(4). 971–981. 221 indexed citations

16.

Afdhal, Nezam H., Claire O’Brien, Eliot Godofsky, et al.. (2007). [6] VALOPICITABINE (NM283), ALONE OR WITH PEG-INTERFERON, COMPARED TO PEG INTERFERON/RIBAVIRIN (PEGIFN/RBV) RETREATMENT IN PATIENTS WITH HCV-1 INFECTION AND PRIOR NON-RESPONSE TO PEGIFN/RBV: ONE-YEAR RESULTS. Journal of Hepatology. 46. S5–S5. 34 indexed citations

17.

Afdhal, Nezam H., Eliot Godofsky, M. Rodríguez‐Torres, et al.. (2006). 39 Valopicitabine (NM283), alone or with peginterferon, compared to peg interferon/ribavirin (pegifn/RBV) re-treatment in hepatitis patients with prior non-response to PEGIFN/RBV: Week 24 results. Journal of Hepatology. 44. S19–S19. 27 indexed citations

18.

Kuritzkes, Daniel R., Jeffrey M. Jacobson, William G. Powderly, et al.. (2004). Antiretroviral Activity of the Anti‐CD4 Monoclonal Antibody TNX‐355 in Patients Infected with HIV Type 1. The Journal of Infectious Diseases. 189(2). 286–291. 149 indexed citations

19.

Bach, Michael C., et al.. (1997). Use of Cerebrospinal Fluid Shunts in Patients Having Acquired Immunodeficiency Syndrome with Cryptococcal Meningitis and Uncontrollable Intracranial Hypertension. Neurosurgery. 41(6). 1280–1283. 42 indexed citations

20.

Godofsky, Eliot, et al.. (1992). Sinusitis in HIV-infected patients: A clinical and radiographic review. The American Journal of Medicine. 93(2). 163–170. 73 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact